Clinical Trial Update: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CD19/CD22 CAR T cells in children and young adults with recurrent or refractory CD19/CD22-expressing B cell malignancies; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia
• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19/CD22 CAR-T cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Status: COMPLETED | Results posted: 2025-06-04